Results of the LEAD-2 study in relation to NICE and ADA/EASD guidelines for the treatment of type 2 diabetes in the UK

Abstract

Guidelines for the management of type 2 diabetes mellitus from the UK National Institute for Health and Clinical Excellence and the joint American Diabetes Association/European Association for the Study of Diabetes identify a role for glucagon-like peptide 1 (GLP-1) agonists as second- or third-line treatments. In the LEAD-2 trial the GLP-1 agonist liraglutide was similar to glimepiride for glycaemic control in patients receiving background metformin. Liraglutide was generally well tolerated, with a low incidence of hypoglycaemia, and it significantly reduced body weight and systolic blood pressure compared with glimepiride. These results suggest that addition of liraglutide may help to improve glycaemic control and reduce body weight and systolic blood pressure in patients with type 2 diabetes who have unsatisfactory control with metformin. Patients who are particularly obese or for whom hypoglycaemia is problematic may be especially suitable for this agent. The future place of liraglutide in guidelines will depend on further data regarding efficacy, tolerability and long-term benefits.

Keywords

clinical trials glucagon-like peptide guidelines liraglutide type 2 diabetes.

Get full access to this article

View all access options for this article.

References

National Collaborating Centre for Chronic Conditions. Clinical Guidelines for type 2 diabetes mellitus: management of blood glucose . London: Royal College of Physicians , 2008.

Nathan DM , Buse JB , Davidson MB et al. Medical management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initia tion and adjustment of therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes . Diabetes Care 2009;32: 193 203 .

Rodbard HW , Blonde L. , Braithwaite SS et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus . Endocr Pract 2007;13(Suppl 1): 1 68 .

National Institute for Health and Clinical Excellence, Centre for Clinical Practice. Type 2 diabetes: newer agents. NICE short clinical guideline 87. London: NICE, 2009.

Marre M. , Shaw J. , Brandle M. et al. Liraglutide, a once daily human GLP 1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD 1 SU) . Diabet Med 2009;26: 268 78 .

Zinman B. , Gerich J. , Buse JB et al. Efficacy and safety of the human GLP 1 analog liraglutide in combination with metformin and TZD in patients with type 2 diabetes mellitus (LEAD 4 Met+TZD) . Diabetes Care (in press).

Russell Jones D. , Vaag A. , Schmitz O. et al. Significantly better glycemic control and weight reduction with liraglutide, a once daily human GLP 1 analog, compared with insulin glargine: all as add on to met formin and a sulfonylurea in type 2 diabetes (LEAD 5) . American Diabetes Association 68th Scientific Sessions , 6 10 June 2008, San Francisco, CA , USA. Abstract 536 P.

Nauck M. , Frid A. , Hermansen K. et al. Liraglutide, a once daily human GLP 1 analogue, in type 2 diabetes provides similar glyc emic control with reduced body weight compared with glimepiride when added to metformin (LEAD 2) . 4th National Conference of the Primary Care Diabetes Society, 21 22 November 2008, Birmingham, UK.

Nauck M. , Frid A. , Hermansen K. et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with met formin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes) 2 study . Diabetes Care 2009;32: 84 90 .

10.

Garber A. , Henry R. , Ratner R. et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD 3 Mono): a randomised, 52 week, phase III, double blind, parallel treatment trial . Lancet 2009;373: 473 81 .

11.

Buse J. , Rosenstock J. , Sesti G. et al. Liraglutide once daily compared to exenatide twice daily for treatment of type 2 diabetes (LEAD 6): a ran domised, 26 week, open label, trial . Lancet 2009 June 8 [Epub ahead of print].

12.

Nauck M. , Stockmann F. , Ebert R. , Creutzfeldt W. Reduced incretin effect in type 2 (non insulin dependent) diabetes . Diabetologia 1986; 29: 46 52 .

13.

Kieffer TJ , McIntosh CH , Pederson RA Degradation of glucose depend ent insulinotropic polypeptide and truncated glucagon like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV . Endocrinology 1995; 136: 3585 96 .

14.

Mentlein R. , Gallwitz B. , Schmidt WE Dipeptidyl peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon like peptide 1(7 36)amide, peptide histidine methionine and is responsible for their degradation in human serum . Eur J Biochem 1993;214: 829 35 .

15.

Nauck MA , Heimesaat MM , Orskov C. et al. Preserved incretin activity of glucagon like peptide 1 [7 36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type 2 diabetes mellitus . J Clin Invest 1993;91: 301 7 .

16.

Knudsen LB , Nielsen PF , Huusfeldt PO et al. Potent derivatives of glucagon like peptide 1 with pharmacokinetic properties suitable for once daily administration . J Med Chem 2000;43: 1664 9 .

17.

Elbrønd B. , Jakobsen G. , Larsen S. et al. Pharmacokinetics, pharmacody namics, safety, and tolerability of a single dose of NN2211, a long acting glucagon like peptide 1 derivative, in healthy male subjects . Diabetes Care 2002;25: 1398 404 .

18.

UK Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) . Lancet 1998;352: 837 53 .

19.

UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood glucose control with metformin on complications in over weight patients with type 2 diabetes (UKPDS 34) . Lancet 1998;352: 854 65 .

20.

Holman RR , Paul SK , Bethel MA et al. 10 year follow up of inten sive glucose control in type 2 diabetes . N Engl J Med 2008;359: 1577 89 .

21.

Patel A. , MacMahon S. , Chalmers J. et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes . N Engl J Med 2008;358: 2560 72 .

22.

Duckworth W. , Abraira C. , Moritz T. et al. Glucose control and vascular complications in veterans with type 2 diabetes . N Engl J Med 2009;360: 129 39 .

23.

Gerstein HC , Miller ME , Byington RP et al. Effects of intensive glucose lowering in type 2 diabetes . N Engl J Med 2008;358: 2545 59 .

24.

Skyler JS , Bergenstal R. , Bonow RO et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association . Circulation 2009;119: 351 7 .

25.

Mellbin LG , Malmberg K. , Norhammar A. et al. The impact of glucose lowering treatment on long term prognosis in patients with type 2 diabetes and myocardial infarction: a report from the DIGAMI 2 trial . Eur Heart J 2008;29: 166 76 .

26.

Nichols GA , Koro CE , Gullion CM et al. The incidence of congestive heart failure associated with antidiabetic therapies . Diabetes Metab Res Rev 2005;21: 51 7 .

27.

Lincoff AM , Wolski K. , Nicholls SJ , Nissen SE Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta analysis of randomized trials . JAMA 2007;298: 1180 8 .

28.

Dluhy RG , McMahon GT Intensive glycemic control in the ACCORD and ADVANCE trials . N Engl J Med 2008;358: 2630 3 .

29.

Drucker DJ , Nauck MA The incretin system: glucagon like peptide 1 receptor agonists and dipeptidyl peptidase 4 inhibitors in type 2 diabetes . Lancet 2006;368: 1696 705 .

30.

Hermansen K. , Mortensen LS Bodyweight changes associated with antihyperglycaemic agents in type 2 diabetes mellitus . Drug Saf 2007; 30: 1127 42 .

31.

Buse JB , Henry RR , Han J. et al. Effects of exenatide (exendin 4) on glycemic control over 30 weeks in sulfonylurea treated patients with type 2 diabetes . Diabetes Care 2004;27: 2628 35 .

32.

Heine RJ , Van Gaal LF , Johns D. et al. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial . Ann Intern Med 2005;143: 559 69 .

33.

Nauck MA , Duran S. , Kim D. et al. A comparison of twice daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non inferiority study . Diabetologia 2007;50: 259 67 .

34.

Zinman B. , Hoogwerf BJ , Durán GS et al. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial . Ann Intern Med 2007;146: 477 85 .

35.

DeFronzo RA , Ratner RE , Han J. et al. Effects of exenatide (exend in 4) on glycemic control and weight over 30 weeks in metformin treated patients with type 2 diabetes . Diabetes Care 2005;28: 1092 100 .

36.

Drucker DJ , Buse JB , Taylor K. et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open label, non inferiority study . Lancet 2008;372: 1240 50 .

37.

Mudaliar S. , Henry RR Incretin therapies: effects beyond glycemic con trol . Am J Med 2009;122: S25 36 .

38.

Ratner R. , Goldberg R. , Haffner S. et al. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the diabe tes prevention program . Diabetes Care 2005;28: 888 94 .

39.

Colagiuri S. , Frid A. , Zdravkovic M. et al. Liraglutide, a human GLP 1 analogue, reduces systolic blood pressure in subjects with type 2 dia betes . 44th European Association for the Study of Diabetes Annual Meeting 7-11 September 2008, Rome, Italy, Abstract 899.

40.

DeFronzo RA , Goodman AM Efficacy of metformin in patients with non insulin dependent diabetes mellitus. The Multicenter Metformin Study Group . N Engl J Med 1995;333: 541 9 .

41.

Aronoff S. , Rosenblatt S. , Braithwaite S. et al. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6 month randomized placebo controlled dose response study. The Pioglitazone 001 Study Group . Diab Care 2000;23: 1605 11 .

42.

Gegick CG , Altheimer MD Comparison of effects of thiazolidinediones on cardiovascular risk factors: observations from a clinical practice . Endocr Pract 2001;7: 162 9 .

43.

Derosa G. , Gaddi AV , Piccinni MN et al. Differential effect of glimepiride and rosiglitazone on metabolic control of type 2 diabetic patients treated with metformin: a randomized, double blind, clinical trial . Diabetes Obes Metab 2006;8: 197 205 .

44.

Hanefeld M. , Patwardhan R. , Jones NP A one year study comparing the efficacy and safety of rosiglitazone and glibenclamide in the treatment of type 2 diabetes . Nutr Metab Cardiovasc Dis 2007;17: 13 23 .

45.

Vilsbøll T. , Zdravkovic M. , Le Thi T. et al. Liraglutide, a long acting human glucagon like peptide 1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes . Diabetes Care 2007;30: 1608 10 .

46.

Matthews DR , Marre M. , Le Thi TD et al. Liraglutide, a human GLP 1 analogue, significantly improves beta cell function in subjects with type 2 diabetes . 44th European Association for the Study of Diabetes Annual Meeting , 7 11 September 2008, Rome , Italy. Abstract 892.